Results 141 to 150 of about 2,682 (215)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert +12 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim To investigate the association between baseline plasma α‐hydroxybutyrate (α‐HB), an organic acid derived from aminoacid catabolism and glutathione anabolism, and the 10‐year incidence of Type 2 diabetes (T2DM). Materials and Methods This prospective study analysed 1349 participants from the Swedish PAROKRANK study.
Elena Fortin +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez +13 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background The role of histone lactylation in diabetes associated renal fibrosis remains poorly defined. In this study, we investigated the contribution of histone H4 lysine 12 lactylation (H4K12la) to abnormal glycolysis and renal fibrogenesis in diabetic kidney disease (DKD) and evaluated sodium butyrate (NaB) as a potential therapeutic ...
Ping He +10 more
wiley +1 more source
Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain +15 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Animal models of prediabetes (Pre‐DM) are essential for studying metabolic disease and testing therapies, yet high‐fat diet (HFD) and HFD‐plus‐streptozotocin (STZ) protocols vary in feeding duration, STZ dose, and diagnostic criteria and rarely account for sex.
Min Xu +7 more
wiley +1 more source